Liraglutide 3.0 mg daily subcutaneous (SQ) injection was the first FDA-approved GLP-1 agonist approved for weight loss in patients with obesity and semaglutide 2.4 mg weekly SQ injection followed shortly after [4]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.